

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-45 (Canceled)

46. (New) Serum-stable amphoteric liposomal formulations with at least one active substance in the aqueous interior, characterized in that the liposomes comprise
 - neutral lipids with a membrane proportion of 10 to 60 mole-%,
 - cholesterol with a proportion of 30 to 50 mole-%,and, as charged lipids, either
 - amphoteric lipids with a proportion of 5 to 30 mole-%,or
 - mixtures of cationic and anionic lipids with an overall proportion of 50 mole-% at maximum,and that the active substance comprises at least one oligonucleotide.
47. (New) The liposomal formulation according to claim 1, characterized in that the proportion of cholesterol is 35 to 45 mole-%, the proportion of amphoteric lipids is 5 to 20 mole-% and/or the proportion of said mixtures is 15 to 45 mole-%.
48. (New) The liposomal formulation according to claim 1, characterized in that the oligonucleotides are constituted of 5-100, preferably 5-40 and more preferably 10-25 deoxyribonucleotides, ribonucleotides or chemically modified derivatives thereof.
49. (New) The liposomal formulation according to claim 1, characterized in that the oligonucleotides are present as single strand, double strand, or in complex folding.
50. (New) The liposomal formulation according to claim 4, characterized in that the

single strands are present as antisense oligonucleotides, the double strands as small interfering RNA and/or decoy oligonucleotides and/or the complex foldings as aptamers and/or spiegelmers.

51. (New) The liposomal formulation according to claim 1, characterized in that the oligonucleotide is an aptamer.

52. (New) The liposomal formulation according to claim 1, characterized in that the oligonucleotide is a spiegelmer.

53. (New) The liposomal formulation according to claim 1, characterized in that the liposomal membrane has the molar composition

DMPC/MoChol/DMPS/Chol 40:10:10:40,
DMPC/AC/Chol 50:10:40,
DMPC/HisChol/DPPS/Chol 35:10:15:40,
DMPC/IsohistsuccDG/Chol 50:10:40,
DMPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/MoChol/DGSucc/Chol 40:10:10:40,
POPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/HistSuccDG/Chol 50:10:40,
POPC/MoChol/DPPS/Chol 40:10:10:40,
DPPC/DOTAP/DGSucc/Chol 20:10:30:40,
DPPC/HistChol/Chol 50:10:40,
DPPC/HistSuccDG/Chol 40:20:40,
DPPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HcChol/Chol 50:15:35,
DPPC/HcChol/Chol 50:15:35,
POPC/HistPS/Chol 50:15:35,
DPPC/HistPS/Chol 50:15:35,

POPC/AC/Chol 50:15:35,
DPPC/AC/Chol 50:15:35,
DPPC/HistChol/Chol 50:15:35,
POPC/HistChol/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HistSuccDG/Chol 50:15:35,
DPPC/IsoHistSuccDG/Chol 50:15:35,
DPPC/HistSuccDG/Chol 50:15:35,
POPC/IsoHistSuccDG/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/MoChol/CHEMS/Chol 40:10:10:40,
DMPC/HistChol/Chol 50:10:40,
POPC/DOTAP/CHEMS/Chol 30:10:20:40,
DMPC/HisChol/DGSucc/Chol 40:10:10:40,
POPC/HisChol/CHEMS/Chol 40:10:10:40,
DMPC/MoChol/CHEMS/Chol 40:10:10:40 or
POPC/MoChol/DGSucc/Chol 30:20:10:40.

54. (New) A method of treating a mammal with a drug comprising administering the drug in the liposomal formulations of claim 1.
55. (New) The method of claim 9 wherein the mammal is a human.
56. (New) The method of claim 9 for parenteral application, preferably intravenous application.
57. (New) The method of claim 9, characterized in that it includes one or more active substances.